Seeking Alpha

Minerva Surgical Announces the Appointment of Kaile Zagger as Chief Commercial Officer

SANTA CLARA, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Minerva Surgical, Inc. (UTRS) (Minerva Surgical), a women's health company focused on solutions to meet the distinct uterine healthcare needs of ...
Nasdaq

Minerva Neurosciences Announces Study Results Demonstrating Bioequivalence of Phase 2b, Phase 3, and Planned Commercial Formulations of Roluperidone for Treatment of Negative ...

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
Seeking Alpha

Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 ...

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...
Business Insider

Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

SOMERSET, N.J. and WALTHAM, Mass., Sept. 24, 2019 /PRNewswire-PRWeb/ -- Catalent, the leading global provider of advanced delivery technologies, development, and ...
Nasdaq

Company to Request Pre-NDA Meeting with U.S. Food and Drug Administration

WALTHAM, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...